These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 32593400)

  • 1. EGFR: An essential receptor tyrosine kinase-regulator of cancer stem cells.
    Talukdar S; Emdad L; Das SK; Fisher PB
    Adv Cancer Res; 2020; 147():161-188. PubMed ID: 32593400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic targeting of the epidermal growth factor receptor in human cancer.
    Dhomen NS; Mariadason J; Tebbutt N; Scott AM
    Crit Rev Oncog; 2012; 17(1):31-50. PubMed ID: 22471663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR-TKIs resistance via EGFR-independent signaling pathways.
    Liu Q; Yu S; Zhao W; Qin S; Chu Q; Wu K
    Mol Cancer; 2018 Feb; 17(1):53. PubMed ID: 29455669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR-mediated autophagy in tumourigenesis and therapeutic resistance.
    Wu M; Zhang P
    Cancer Lett; 2020 Jan; 469():207-216. PubMed ID: 31639425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER family in cancer progression: From discovery to 2020 and beyond.
    Kumar R; George B; Campbell MR; Verma N; Paul AM; Melo-Alvim C; Ribeiro L; Pillai MR; da Costa LM; Moasser MM
    Adv Cancer Res; 2020; 147():109-160. PubMed ID: 32593399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The TGFβ-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells.
    Wang T; Wang D; Zhang L; Yang P; Wang J; Liu Q; Yan F; Lin F
    J Exp Clin Cancer Res; 2019 May; 38(1):226. PubMed ID: 31138318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo modeling of the EGFR family in breast cancer progression and therapeutic approaches.
    Simond AM; Muller WJ
    Adv Cancer Res; 2020; 147():189-228. PubMed ID: 32593401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms.
    Yamaoka T; Ohba M; Ohmori T
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29140271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms.
    Aldonza MBD; Ku J; Hong JY; Kim D; Yu SJ; Lee MS; Prayogo MC; Tan S; Kim D; Han J; Lee SK; Im SG; Ryu HS; Kim Y
    Sci Adv; 2020 Feb; 6(6):eaav7416. PubMed ID: 32083171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emodin suppresses maintenance of stemness by augmenting proteosomal degradation of epidermal growth factor receptor/epidermal growth factor receptor variant III in glioma stem cells.
    Kim J; Lee JS; Jung J; Lim I; Lee JY; Park MJ
    Stem Cells Dev; 2015 Feb; 24(3):284-95. PubMed ID: 25229646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.
    Wykosky J; Fenton T; Furnari F; Cavenee WK
    Chin J Cancer; 2011 Jan; 30(1):5-12. PubMed ID: 21192840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The quest to overcome resistance to EGFR-targeted therapies in cancer.
    Chong CR; Jänne PA
    Nat Med; 2013 Nov; 19(11):1389-400. PubMed ID: 24202392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
    Juchum M; Günther M; Laufer SA
    Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insight into the medicinal chemistry of EGFR and HER-2 inhibitors.
    Wang C; Gao H; Dong J; Wang F; Li P; Zhang J
    Curr Med Chem; 2014; 21(11):1336-50. PubMed ID: 24251571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
    Hsu PC; Jablons DM; Yang CT; You L
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. V843I, a lung cancer predisposing EGFR mutation, is responsible for resistance to EGFR tyrosine kinase inhibitors.
    Matsushima S; Ohtsuka K; Ohnishi H; Fujiwara M; Nakamura H; Morii T; Kishino T; Goto H; Watanabe T
    J Thorac Oncol; 2014 Sep; 9(9):1377-84. PubMed ID: 25057940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor.
    Zhang Y
    Pharmacol Rev; 2023 Nov; 75(6):1218-1232. PubMed ID: 37339882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR and NF-κB: partners in cancer.
    Shostak K; Chariot A
    Trends Mol Med; 2015 Jun; 21(6):385-93. PubMed ID: 25979753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.